FAIR VALUE - Narrative (Details)		1 Months Ended	3 Months Ended
	May 20, 2020 USD ($)	May 31, 2020 USD ($)	Jun. 30, 2020 USD ($)	Mar. 31, 2020 $ / shares	Sep. 30, 2020 USD ($)	Dec. 31, 2019 USD ($)
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Short-term contingent consideration					$ 6,475,000	$ 0
Long-term contingent consideration					$ 35,188,000	$ 168,000
Collegium warrants
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Proceeds from sale of investments		$ 6,000,000.0
Investment, carrying value derecognized		$ 6,500,000
Loss on sale of investments			$ 500,000
Collegium Pharmaceutical Inc | Receivables from Collegium
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Warrant, fair value price (in dollars per share) | $ / shares				$ 16,330,000
Discounted Cash Flow | Discount rate
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input					0.105
Collegium Pharmaceutical Inc | Receivables from Collegium
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Warrant, expected term				2 years 7 months 9 days
Warrant, risk-free rate				0.27%
Warrant, remaining contractual period				2 years 7 months 9 days
Zyla Life Sciences
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration liability					$ 41,700,000
Short-term contingent consideration					6,500,000
Long-term contingent consideration					$ 35,200,000
INDOCIN | Zyla Life Sciences | Option Pricing Model
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration, future royalties, estimated revenue, period	10 years
INDOCIN | Zyla Life Sciences | Discounted Cash Flow | Discount rate
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration, future royalties, present value rate, percent	10.00%
INDOCIN | Zyla Life Sciences | Iroko
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent payment consideration, future royalties covenant, product net sales (over)	$ 20,000,000.0